搜索
Search
img

News Center

新闻中心

Kintor Pharmaceutical Selected as the Excellent Case of Advanced Enterprises in 2020 Science and Technology Innovation by People.cn

  • Time of issue:2020-10-27

(Summary description)Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.

Kintor Pharmaceutical Selected as the Excellent Case of Advanced Enterprises in 2020 Science and Technology Innovation by People.cn

(Summary description)Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-10-27 10:18
  • Views:
Information

On October 27, 2020, the “2020 Science and Technology Innovation Enterprise Frontier Summit and the First People.cn Science and Excellent Case of the Technology Innovation Enterprise” sponsored by People.cn was held in the New Media Building of People’s Daily. As one of the core topics, the summit focused on the opportunities and challenges of innovation in China’s biomedicine industry, and established an exchange platform between the government, industry and research institutes to promote further development of the biomedicine industry.

 

At the same time, the summit published the “Excellent Case of Advanced Enterprises in 2020 Science and Technology Innovation of People.cn”, aiming to explore the most potential representatives of emerging science and technology and enterprise innovation. Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts. This election represents high recognition of the Company's performance in the industry.

 

2020 is the closing year of the “13th Five-Year Plan” and the opening year of the “14th Five-Year Plan”. Kintor Pharmaceutical will continue to increase investment in R&D of its core product lines, continuously improve innovative research and development capabilities and construction of industrialization platforms, and contribute to the innovative development and industrialization upgrading of China’s biomedicine industry.

Scan the QR code to read on your phone